ISTA: ISTA Pharmaceuticals, Inc. StockTalks

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, July 5, 2012, 6:09 PM After going private in 2007, eye care giant Bausch + Lomb may be considering an IPO before year-end. According to reports, the company is seeking to bulk-up via acquisitions, a thesis reinforced by its recent $600M acquisition of ISTA Pharmaceuticals (ISTA). Comment! [Healthcare]
Tuesday, March 27, 2012, 9:03 AM Premarket gainers: OPXT +55%. WNC +9%. ISTA +8%. DANG +5%. RBS +3%. ARNA +3%. LEN +3%.
Losers: MAPP -17%. MMR -16%. APOL -6%. NBG -6%. TOT -6%. OCLR -3%. EXPE -3%. HEK -3%. EXXI -3%. Comment! [On the Move]
Monday, March 26, 2012, 5:57 PM Bausch + Lomb acquires ISTA Pharmaceuticals (ISTA) for $500M, or $9.10 per share in cash. The transaction is expected to strengthen Bausch + Lomb's overall product pipeline and is expected to close in 2Q12. Comment! [Healthcare, M&A]
Thursday, February 23, 2012, 5:12 PM ISTA Pharmaceuticals (ISTA): Q4 EPS of $0.25 beats by $0.04. Revenue of $45.1M (-11.7% Y/Y) misses by $1.5M. (PR) Comment! [Earnings, Healthcare]
Wednesday, February 1, 2012, 2:29 PM A SEC filing reveals that hedge fund Loeb Arbitrage holds a 5.06% stake in Ista Pharmaceuticals (ISTA +1.4%) with all the shares on record being purchased since the end of Q3. Comment! [Healthcare]
Monday, January 30, 2012, 8:06 AM Valeant Pharmaceuticals (VRX) withdraws its buyout offer of $7.50 per share for ITSA Pharmaceuticals (ISTA) due to what it calls a "lack of progress" with ISTA's management team. Shares of ISTA -8.4% premarket. Comment! [Healthcare, On the Move, M&A]
Tuesday, January 17, 2012, 9:25 AM Premarket gainers: VQ +50%. CNVO +48%. DNN +17%. PVX +15%. TSLA +15%. ISTA +11%. EK +10%. ING +8%. AEG +8%. FRO +8%. AVL +7%. QCOR +7%. BRD +6%. NBG +6%. RBS +6%. NOK +6%. TTM +5%. JASO +5%. MTL +4%. BHP +4%. SINA +4%. RIO +4%. ASML +4%. HMA +4%. WFR +4%. GMCR +3%. TSL +3%. HL +3%. AVNR +3%. HMY +3%. NDCO +3%. CLWR +3%. BIDU +3%. TOT +3%. BSBR +3%. BUD +3%. FCX +3%. CS +3%.
Losers: CUK -16%. CCL -15%. KGC -8%. RCL -7%. C -5%. MTG -5%. Comment! [On the Move]
Tuesday, January 17, 2012, 2:29 AM Valeant Pharmaceuticals (VRX) raised its offer for ISTA Pharmaceuticals (ISTA) to $7.50/share from an initial $6.50/share, and set a target price of $8.50/share subject to a week of due diligence, according to an ISTA statement. ISTA officials say they're considering the revised offer but are also in talks with other companies. (previously) Comment! [Healthcare, M&A]
Friday, January 6, 2012, 10:33 AM Shares of Valeant (VRX -2.3%) hit some volatility this morning after its 2012 guidance presentation. The company sees Q4 earnings in the mid-range of estimates, while it ups 2012 EPS estimates to between $3.95 - $4.20. More importantly, the company says there's still no agreement on the buyout process or price with Ista Pharmaceuticals (ISTA -0.4%), following Ista's rejection of its recent bid in December, and puts a drop dead date of January 31 for negotiations. Comment! [Healthcare, On the Move]
Friday, January 6, 2012, 8:03 AM ISTA Pharmaceuticals (ISTA) announces that it landed a U.S. patent allowance for Prolensa along with partner Senju Pharmaceuticals. The firm says it anticipates filing a New Drug Application with the FDA for Prolensa in H1, with a commercial launch expected in early 2013. Comment! [Healthcare]
Wednesday, January 4, 2012, 4:44 PM ISTA Pharmaceuticals (ISTA) says during its guidance and pipeline update that it expects 2012 earnings and revenue to come in below estimates. It now expects its EPS to be between $0.28 - $0.39 on revenue of around $180M -$195M. Comment! [Healthcare]
Friday, December 16, 2011, 11:09 AM The board of ISTA Pharmaceuticals (ISTA +68.1%) confirms that it rejected Valeant Pharmaceuticals' (VRX -0.5%) offer of $6.50/share, calling it "grossly inadequate." Comment! [Healthcare, On the Move]
Friday, December 16, 2011, 7:54 AM Valeant Pharmaceuticals (VRX) offers $314M or $6.50/share in cash for ISTA Pharmaceuticals (ISTA +60%), a 67% premium to Thursday's close. (PR) Comment! [M&A, Breaking News, On the Move, Healthcare]
Thursday, October 13, 2011, 1:02 PM ISTA Pharmaceuticals (ISTA -5.3%) trades lower after reporting mixed results from its eye drug trials. Phase 3 studies to evaluate the short-term safety and efficacy of its drug Remura, a treatment for dry eye disease, showed it was effective but not statistically better than the placebo. 1 Comment [Healthcare, On the Move]
Friday, July 29, 2011, 10:39 AM ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M (+6% Y/Y) and -$0.11, below a consensus of $41.9M and $0.05. Perhaps more importantly, ISTA is also reporting that a a Phase 3 study for its REMURA drug for treating dry eye disease showed that the drug "was not statistically significantly better" than a placebo. Comment! [Healthcare, On the Move, Earnings]
Monday, October 18, 2010, 9:00 AM Premarket gainers: KWK +15%. ISTA +15%. PPHM +9%. GNBT +8%. STX +6%. FBP +6%. STEM +6%. AGN +5%. PIP +5%.
Losers: PETS -13%. MMR -4%. Comment!

ISTA ISTA Pharmaceuticals, Inc.

ISTA

ISTA Pharmaceuticals, Inc.